We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+11.17%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$469M
AUM Growth
+$65.3M
Cap. Flow
+$30.3M
Cap. Flow %
6.45%
Top 10 Hldgs %
67.79%
Holding
39
New
8
Increased
4
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$27.4M
2
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$24.2M
3
CBIO
Crescent Biopharma
CBIO
+$16.9M
4
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$8.47M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$6.24M

Top Sells

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$19.2M
2
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$11.4M
3
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$8.82M
4
QLTI
QLT Inc
QLTI
+$5.3M
5
LOXO
Loxo Oncology, Inc
LOXO
+$2.05M

Sector Composition

Rank Sector Weight
1 Healthcare 70.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$58.6M 12.49%
2,895,251
+255,000
+10% +$4.63M
CYTK icon
2
Cytokinetics
CYTK
$10.9B
$47.3M 10.09%
4,989,218
+648,489
+15% +$5.32M
CCXI
3
DELISTED
ChemoCentryx, Inc.
CCXI
$36.7M 7.83%
8,182,052
– –
CNCE
4
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$30.9M 6.59%
2,755,318
– –
ARRY
5
DELISTED
Array Biopharma Inc
ARRY
$29.4M 6.27%
8,260,897
+410,686
+5% +$1.34M
FWP
6
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$25.9M 5.51%
203,516
-2,382
-1% -$321K
IONS icon
7
Ionis Pharmaceuticals
IONS
$8.85B
$19.8M 4.22%
+850,000
New +$27.4M
CBIO
8
Crescent Biopharma
CBIO
$555M
$17.8M 3.79%
+24,474
New +$16.9M
CASC
9
DELISTED
Cascadian Therapeutics, Inc.
CASC
$17.7M 3.78%
3,133,228
– –
OMED
10
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$16.5M 3.51%
1,339,336
– –
TBRA
11
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$15.7M 3.35%
1,253,401
– –
CTIC
12
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$15.2M 3.24%
4,479,694
– –
ARQL
13
DELISTED
Arqule Inc
ARQL
$14.2M 3.02%
7,450,128
-443,196
-6% -$751K
XENE icon
14
Xenon Pharmaceuticals
XENE
$6.2B
$10.5M 2.24%
1,775,572
– –
ALPN
15
DELISTED
Alpine Immune Sciences Inc
ALPN
$8.86M 1.89%
481,611
+94,925
+25% +$1.68M
VTAE
16
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$8.21M 1.75%
761,079
-1,327,935
-64% -$11.4M
PRTK
17
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$8M 1.7%
+575,000
New +$8.47M
INFI
18
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$6.9M 1.47%
+5,184,600
New +$24.2M
ONCT
19
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$6.33M 1.35%
8,223
– –
CTMX icon
20
CytomX Therapeutics
CTMX
$714M
$6.19M 1.32%
606,138
– –
KDNY
21
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$5.81M 1.24%
+102,721
New +$6.24M
MGNX icon
22
MacroGenics
MGNX
$240M
$5.4M 1.15%
+200,000
New +$4.51M
ESPR
23
DELISTED
Esperion Therapeutics
ESPR
$4.93M 1.05%
499,142
-107,659
-18% -$1.78M
FLNA
24
Filana Therapeutics
FLNA
$46.4M
$4.71M 1%
307,130
– –
QLTI
25
DELISTED
QLT Inc
QLTI
$3.2M 0.68%
2,255,476
-3,446,133
-60% -$5.3M
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2016 Portfolio in Review

As of Q2 2016, BVF Inc held 39 positions worth $469M, up 16% from $404M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

BVF Inc deployed $30.3M of net new capital in Q2 2016, opening 8 new positions and adding to 4 existing holdings. Its largest new stake was Ionis Pharmaceuticals: 850,000 shares worth $19.8M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 64% a quarter earlier.

On the sell side, the largest reduction was VITAE PHARMACEUTICALS INC COMMON STOCK, an estimated $11.4M trimmed.

  • BVF Inc's largest Q2 2016 buy was Ionis Pharmaceuticals: 850,000 shares worth $19.8M.
  • BVF Inc added most to Cytokinetics in Q2 2016, an estimated $5.32M increase.
  • BVF Inc's biggest Q2 2016 reduction was VITAE PHARMACEUTICALS INC COMMON STOCK, cutting an estimated $11.4M.
  • BVF Inc fully exited Ironwood Pharmaceuticals in Q2 2016, selling an estimated $19.2M.
  • BVF Inc's ten largest holdings make up 68% of its $469M portfolio in Q2 2016.
  • BVF Inc opened 8 new positions and closed 5 in Q2 2016.
  • BVF Inc's portfolio value rose 16% quarter-over-quarter to $469M.

Based on BVF Inc's 13F filing for Q2 2016, filed 15 Aug 2016.